FDA Picks Eli Lilly, Regeneron for Fast-Track Manufacturing Review
The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck Pilot Program to accelerate manufacturing facility reviews.
The U.S. Food and Drug Administration has chosen Eli Lilly and Regeneron as two of the first seven companies to participate in its newly launched PreCheck Pilot Program, a regulatory initiative designed to speed up the review and approval of new pharmaceutical manufacturing facilities, according to reporting from CNBC.
The selection signals a meaningful shift in how the agency intends to handle manufacturing oversight — an area that has historically been a bottleneck in bringing new drugs to market. By pre-qualifying certain manufacturers for expedited review, the FDA appears to be acknowledging that the conventional inspection and approval timeline can delay patient access to medicines, particularly as domestic drug production becomes a national priority.
Read more AMASS Brands to Buy Majority Stake in HpO Protein Water →
The inclusion of Eli Lilly and Regeneron is notable given both companies' prominence in high-demand therapeutic areas. Lilly has faced intense pressure to scale up manufacturing capacity for its weight-loss and diabetes drugs, while Regeneron has expanded its biologics pipeline considerably in recent years. Being selected for a pilot program of this nature suggests these firms met specific compliance and operational benchmarks the FDA used to identify early participants.
The PreCheck program reflects a broader regulatory philosophy gaining traction in Washington: that modernizing the FDA's operational processes — not just its scientific standards — is essential to keeping pace with the speed of pharmaceutical innovation and the demands of a post-pandemic supply chain environment. If the pilot demonstrates measurable gains in review efficiency without compromising safety, it could be expanded to a wider pool of manufacturers.
Continue reading at US Top News and Analysis.
